- Home
- SDIG vs RPTX Comparison
SDIG vs RPTX Comparison
Compare SDIG & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDIG
- RPTX
- Stock Information
- Founded
- SDIG 2021
- RPTX 2016
- Country
- SDIG United States
- RPTX Canada
- Employees
- SDIG N/A
- RPTX N/A
- Industry
- SDIG Investment Bankers/Brokers/Service
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- SDIG Finance
- RPTX Health Care
- Exchange
- SDIG Nasdaq
- RPTX Nasdaq
- Market Cap
- SDIG 52.7M
- RPTX 54.0M
- IPO Year
- SDIG 2021
- RPTX 2020
- Fundamental
- Price
- SDIG $3.08
- RPTX $1.29
- Analyst Decision
- SDIG Buy
- RPTX Strong Buy
- Analyst Count
- SDIG 3
- RPTX 3
- Target Price
- SDIG $7.25
- RPTX $7.00
- AVG Volume (30 Days)
- SDIG 177.0K
- RPTX 231.9K
- Earning Date
- SDIG 03-05-2025
- RPTX 03-03-2025
- Dividend Yield
- SDIG N/A
- RPTX N/A
- EPS Growth
- SDIG N/A
- RPTX N/A
- EPS
- SDIG N/A
- RPTX N/A
- Revenue
- SDIG $76,388,781.00
- RPTX $66,524,000.00
- Revenue This Year
- SDIG $1.23
- RPTX $12.15
- Revenue Next Year
- SDIG $40.59
- RPTX N/A
- P/E Ratio
- SDIG N/A
- RPTX N/A
- Revenue Growth
- SDIG N/A
- RPTX 18.19
- 52 Week Low
- SDIG $1.65
- RPTX $1.10
- 52 Week High
- SDIG $6.70
- RPTX $7.45
- Technical
- Relative Strength Index (RSI)
- SDIG 34.38
- RPTX 47.52
- Support Level
- SDIG $3.31
- RPTX $1.13
- Resistance Level
- SDIG $3.53
- RPTX $1.37
- Average True Range (ATR)
- SDIG 0.23
- RPTX 0.09
- MACD
- SDIG 0.01
- RPTX 0.04
- Stochastic Oscillator
- SDIG 11.59
- RPTX 57.14
About SDIG Stronghold Digital Mining Inc.
Stronghold Digital Mining Inc is a vertically integrated crypto asset mining company currently focused on mining Bitcoin. The company has two reporting segments; Energy Operations and Cryptocurrency Operations. It generates maximum revenue from the Cryptocurrency Operations segment.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.